Cargando…
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease
Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142612/ https://www.ncbi.nlm.nih.gov/pubmed/37111380 http://dx.doi.org/10.3390/ph16040623 |
_version_ | 1785033654861299712 |
---|---|
author | Kim, Gi-Ae Cho, Hyun Chin Jeong, Soung Won Kang, Bo-Kyeong Kim, Mimi Jung, Seungwon Hwang, Jungwook Yoon, Eileen L. Jun, Dae Won |
author_facet | Kim, Gi-Ae Cho, Hyun Chin Jeong, Soung Won Kang, Bo-Kyeong Kim, Mimi Jung, Seungwon Hwang, Jungwook Yoon, Eileen L. Jun, Dae Won |
author_sort | Kim, Gi-Ae |
collection | PubMed |
description | Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind, placebo-controlled 2a study in patients with NAFLD (MRI-proton density fat fraction [MRI-PDFF] ≥ 8% and liver fibrosis ≥ 2.5 kPa on MR elastography [MRE]) in Korea. Patients were randomly assigned to 1800 mg ALS-L1023 (n = 19), 1200 mg ALS-L1023 (n = 21), or placebo (n = 17) groups. Efficacy endpoints included changes in liver fat on MRI-PDFF, liver stiffness on MRE, and liver enzymes. For the full analysis set, a relative hepatic fat reduction from baseline was significant in the 1800 mg ALS-L1023 group (−15.0%, p = 0.03). There was a significant reduction in liver stiffness from baseline in the 1200 mg ALS-L1023 group (−10.7%, p = 0.03). Serum alanine aminotransferase decreased by −12.4% in the 1800 mg ALS-L1023 group, −29.8% in the 1200 mg ALS-L1023 group, and −4.9% in the placebo group. ALS-L1023 was well tolerated and there were no differences in the incidence of adverse events among the study groups. ALS-L1023 could reduce hepatic fat content in patients with NAFLD. |
format | Online Article Text |
id | pubmed-10142612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101426122023-04-29 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease Kim, Gi-Ae Cho, Hyun Chin Jeong, Soung Won Kang, Bo-Kyeong Kim, Mimi Jung, Seungwon Hwang, Jungwook Yoon, Eileen L. Jun, Dae Won Pharmaceuticals (Basel) Article Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind, placebo-controlled 2a study in patients with NAFLD (MRI-proton density fat fraction [MRI-PDFF] ≥ 8% and liver fibrosis ≥ 2.5 kPa on MR elastography [MRE]) in Korea. Patients were randomly assigned to 1800 mg ALS-L1023 (n = 19), 1200 mg ALS-L1023 (n = 21), or placebo (n = 17) groups. Efficacy endpoints included changes in liver fat on MRI-PDFF, liver stiffness on MRE, and liver enzymes. For the full analysis set, a relative hepatic fat reduction from baseline was significant in the 1800 mg ALS-L1023 group (−15.0%, p = 0.03). There was a significant reduction in liver stiffness from baseline in the 1200 mg ALS-L1023 group (−10.7%, p = 0.03). Serum alanine aminotransferase decreased by −12.4% in the 1800 mg ALS-L1023 group, −29.8% in the 1200 mg ALS-L1023 group, and −4.9% in the placebo group. ALS-L1023 was well tolerated and there were no differences in the incidence of adverse events among the study groups. ALS-L1023 could reduce hepatic fat content in patients with NAFLD. MDPI 2023-04-20 /pmc/articles/PMC10142612/ /pubmed/37111380 http://dx.doi.org/10.3390/ph16040623 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Gi-Ae Cho, Hyun Chin Jeong, Soung Won Kang, Bo-Kyeong Kim, Mimi Jung, Seungwon Hwang, Jungwook Yoon, Eileen L. Jun, Dae Won A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title_full | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title_fullStr | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title_full_unstemmed | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title_short | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease |
title_sort | phase 2a, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of als-l1023 in non-alcoholic fatty liver disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142612/ https://www.ncbi.nlm.nih.gov/pubmed/37111380 http://dx.doi.org/10.3390/ph16040623 |
work_keys_str_mv | AT kimgiae aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT chohyunchin aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jeongsoungwon aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT kangbokyeong aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT kimmimi aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jungseungwon aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT hwangjungwook aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT yooneileenl aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jundaewon aphase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT kimgiae phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT chohyunchin phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jeongsoungwon phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT kangbokyeong phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT kimmimi phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jungseungwon phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT hwangjungwook phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT yooneileenl phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease AT jundaewon phase2arandomizeddoubleblindplacebocontrolledstudytoassesstheefficacyandsafetyofalsl1023innonalcoholicfattyliverdisease |